Drugs / SB-4826
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07222631 | Feb 2026 → Feb 2031 expected | cancer, non-Hodgkin lymphoma | University of California, San Diego | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-4826 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07222631 ↗ |
| Route | Oral | “orally bioavailable small ubiquitin-like modifier (SUMO) E1 inhibitor SB-4826” NCT07222631 ↗ |